Based on a cost-effectiveness analysis, researchers found that PCT is the most cost-effective management modality for LAGC compared to upfront surgery (US). PCT yielded 3.11 quality-adjusted life-years (QALYs) at a cost of $40,792.16, while US yielded 3.15 QALYs at a cost of $55,575.57. The incremental cost-effectiveness ratio (ICER) was $369,585.25. Sensitivity analyses consistently favored PCT, and across 100,000 simulations, 100% of trials favored PCT as the most cost-effective treatment option for LAGC.
Journal Article by Prasath V, Quinn PL (…) Chokshi RJ et 6 al. in Am Surg